Burkholderia
Related VFcategory: Motility
Target: Not determined
Drug effect: Reduces the mortality, and potentiates the biofilm inhibiting effect of ceftazidime.
Max phase: Preclinical (in vivo)
Publication: Bove M, et al., 2022. The anti-virulence activity of the non-mevalonate pathway inhibitor FR900098 towards Burkholderia cenocepacia is maintained during experimental evolution. Microbiology (Reading) 168(3):10.1099/mic.0.001170.